Ted Kaptchuk in an NCCIH interview about the use of placebos in research
Ted Jack Kaptchuk (born August 17, 1947) is an American medical researcher who holds professorships in medicine and in global health and social medicine at Harvard Medical School. He researches the placebo effect within the field of placebo studies.
Kaptchuk had an herbal and acupuncture clinic in Boston for many years starting in 1976.[2] In the 1980s he was clinical director of the Pain Unit at Lemuel Shattuck Hospital.[3] In 1990, he became associate director of the Center for Alternative Medicine Research and Education at Beth Israel Deaconess Medical Center, also in Boston.[2] In 2011, he became Director of the Harvard Program in Placebo Studies and the Therapeutic Encounter at Beth Israel Deaconess.[2][4] Although he does not have a medical degree,[2] he has been a faculty member at Harvard Medical School since 1998, a professor of medicine since 2013, and professor of global health and social medicine since 2015.[3]
Working with Kathryn T. Hall and others Kaptchuk has led many studies of the placebo effect, including the role of genetic markers that identify people who people who respond best to placebos.[5] Some of this work suggests that placebos may still work despite disclosure that they are placebos.[6][7]
Kaptchuk has served on panels for the NIH and FDA, and worked as a medical writer for the BBC.[8] He has written more than 300 peer-reviewed publications (h-index=100, i-index=275).[9]
Kaptchuk has been awarded three Lifetime Achievement Awards including Society of Acupuncture in 2015, Society of Interdisciplinary Placebo Studies in 2021, and the William Silen Lifetime Achievement Award in Mentoring from Harvard Medical School in 2022.[10][11]
On October 10, 2023, an article, entitled "No Better Than Placebo", in The New York Times by Kaptchuk noted that some current medicines on store shelves were found to be "ineffective" (notwithstanding the "1962 Drug Efficacy Amendment" of the "Federal Food, Drug, and Cosmetic Act") based on studies and acted, if at all, as placebos. Kaptchuk concluded that "placebo effects can be significantly enhanced in the context of a supportive, respectful and attentive patient-relationship"[12] after recalling his earlier studies showing that "non-specific effects can produce statistically and clinically significant outcomes and the patient-practitioner relationship is the most robust component"[13] and "open label placebo could offer a possible supplementary intervention in some chronic conditions and an honest approach for a watch-and-wait strategy".[14]
